Reports Q3 revenue $52,000 vs. $20,000 last year. Cash and cash equivalents and marketable securities on September 30, 2024, were $2.9 million, as compared to $1.5 million as of December 31, 2023.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCNX:
- Vaccinex provides update on ActivMAb platform
- Vaccinex to preset new biomarker data on HNSCC
- Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab
- Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study
- Vaccinex files to sell 1.6M shares of common stock for holders